- Evaluating the cost-effectiveness of a conservative approach to oxygen therapy for invasively ventilated adults in intensive care: the UK-ROX trial. [Journal Article]Value Health. 2026 Oct 01. [Online ahead of print]VH
- CONCLUSIONS: Conservative and usual oxygen therapy resulted in similar QALYs, and while conservative therapy appeared cost-saving with positive INBs, both estimates have uncertainty.
- Publisher Full Text (DOI)
- Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation. [Journal Article]Value Health. 2026 Sep 29. [Online ahead of print]VH
- CONCLUSIONS: Modelled 5-year impacts of semaglutide treatment suggest potential wide-ranging individual, healthcare and societal benefits across cardiometabolic comorbidities that are not captured in traditional narrow healthcare perspectives.
- Publisher Full Text (DOI)
- Recommendations on the Implementation of Performance Outcome Assessments in Clinical Trials: A Good Practices Report of an ISPOR Task Force. [Review]Value Health. 2026 Sep 28. [Online ahead of print]VH
- Performance outcome (PerfO) assessments are standardized, task-based clinical outcome assessments (COAs) used to evaluate patients' physical, cognitive, sensory, and functional abilities in clinical trials. Building on the first ISPOR PerfO Task Force report, which addressed selection, development, and modification of PerfO instruments, this second task force report focuses on clinical trial impl…
- Publisher Full Text (DOI)
- Barriers and facilitators to implementing patient-reported outcome and experience measures (PROMs/PREMs) in health systems: a comprehensive overview of systematic reviews. [Review]Value Health. 2026 Sep 28. [Online ahead of print]VH
- CONCLUSIONS: PROM and PREM programmes should prioritize workflow and IT integration, inclusive design of measures and platforms, clear ownership, and support for patients and clinicians. This review can guide implementation investment, local pre-implementation work, and evaluations.
- Publisher Full Text (DOI)
- Signaling Demand with Cost-Effectiveness Analysis: A Case Study of PCSK9 Inhibitors. [Journal Article]Value Health. 2026 Sep 25. [Online ahead of print]VH
- CONCLUSIONS: We developed a framework that characterizes the demand curve implied by heterogeneity in cost-effectiveness and demonstrates how treatment recommendations can be used to signal demand to manufacturers. Applied to PCSK9-I therapy, the framework characterized the relationship between treatment price and eligibility and its implications for treatment access, surplus distribution, and value-based pricing.
- Publisher Full Text (DOI)
- Cost-Effectiveness and Clinical Utility of a Retinal Cardiovascular AI-Guided Strategy for Statin Initiation: A South Korean Multicenter Prospective Study. [Journal Article]Value Health. 2026 Sep 24. [Online ahead of print]VH
- CONCLUSIONS: Linking retinal cardiovascular AI outputs to guideline-based preventive care was associated with more guideline-concordant statin decisions and, in a lifetime model, was projected to be economically dominant over usual care. Long-term outcomes were projected, not observed, and require confirmation in other settings.
- Publisher Full Text (DOI)
- Sources of the utilities used in paediatric cost-utility analyses in children aged under 5 years, and the methods used in their elicitation: a systematic review. [Review]Value Health. 2026 Sep 24. [Online ahead of print]VH
- CONCLUSIONS: CUAs involving children under five years have increased; but the methods for obtaining utilities remain varied and underreported. The frequent reliance on adult MAUIs and utilities underscores the need for validated age-appropriate instruments to improve the validity of QALY estimates in this age group.
- Publisher Full Text (DOI)
- CONFIRMATORY VALIDATION AND CLUSTER CLASSIFICATION OF THE IRRITABLE BOWEL SYNDROME SYMPTOM SEVERITY SCALE (IBS-SSS). [Journal Article]Value Health. 2026 Sep 23. [Online ahead of print]VH
- CONCLUSIONS: The IBS-SSS demonstrates strong psychometric validity and effectively distinguishes symptom severity. Findings highlight the heterogeneity of IBS and support symptom-based, personalised approaches over subtype-based classification.
- Publisher Full Text (DOI)
- The Implementation of NICE Severity Modifier in the Single Technology Appraisal of Mirvetuximab Soravtansine: External Assessment Group Perspective. [Editorial]Value Health. 2026 Sep 21. [Online ahead of print]VH
- CONCLUSIONS: Severity-modifier decisions can change under plausible modelling assumptions, particularly when estimates are close to the threshold between weights. When severity weights are used, appraisals should include a standard sensitivity analysis reporting the absolute QALY shortfall, proportional QALY shortfall and resulting severity weight under alternative assumptions. Clearer reporting of these calculations would make the basis for severity-weight decisions easier to scrutinise across appraisals.
- Publisher Full Text (DOI)
- Cost-Effectiveness Analysis of the Five First-line Treatment Regimens for ALK-positive NSCLC in China: An Economic Evaluation Based on Network Meta-Analysis. [Journal Article]Value Health. 2026 Sep 21. [Online ahead of print]VH
- CONCLUSIONS: For patients with advanced ALK-positive NSCLC in China, lorlatinib, alectinib, brigatinib, and iruplinalkib are cost-effective compared to crizotinib, with the exception of ensartinib. Among these, iruplinalkib is the most cost-effective TKI for first-line treatment, followed by lorlatinib.
- Publisher Full Text (DOI)
- Generative Artificial Intelligence for Systematic Literature Reviews: A Good Practices Report of an ISPOR Special Task Force. [Review]Value Health. 2026 Sep 19. [Online ahead of print]VH
- CONCLUSIONS: Based on current evidence, GenAI can augment, but not replace, human expertise in SLRs. Responsible use requires evaluating GenAI suitability for each review task, retaining human accountability at all decision points, and documenting AI use as a core methodological component. Because GenAI evolves rapidly, these recommendations reflect evidence through July 2025 and warrant periodic updating.
- Publisher Full Text (DOI)
- Health Technology Assessment Lifecycle Concepts: A Scoping Review Outlining the Change in Policies to Manage Uncertainties Associated With Reimbursement of Medicines. [Journal Article]Value Health. 2026 Sep 16. [Online ahead of print]VH
- CONCLUSIONS: The anticipatory nature and content of activities within LC-HTA led to it emerging as the most appropriate for addressing the clinical and financial risks to the initial reimbursement decisions for contemporary medicines. Both capacity building and further development of triaging for risk-based reimbursement pathway assignment can aid in the implementation of LC-HTA in practice.
- Publisher Full Text (DOI)
- Cost-Effectiveness of Cilta-cel in Lenalidomide-Refractory Multiple Myeloma: An Analysis of the CARTITUDE-4 Trial. [Journal Article]Value Health. 2026 Sep 11. [Online ahead of print]VH
- CONCLUSIONS: Relative to standard therapy, cilta-cel is projected to exhibit an economic absolute cost-effectiveness advantage in the treatment of lenalidomide-refractory multiple myeloma.
- Publisher Full Text (DOI)
- An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole-Genome Sequencing in Advanced Non-small-Cell Lung Cancer. [Journal Article]Value Health. 2026 Sep 09. [Online ahead of print]VH
- CONCLUSIONS: Our structured approach effectively identified items in the original analysis requiring updates and provides a foundation for further developing a checklist to guide iterative HTA. Continued monitoring and assessment of new treatment options, the dynamic diagnostics and costs throughout the life-cycle remain necessary to determine when WGS can be considered cost-effective.
- Publisher Full Text (DOI)